Latest News on AZTA

Financial News Based On Company


Advertisement
Advertisement

Azenta Updates FreezerPro Software to Strengthen Sample Traceability

https://clpmag.com/lab-management/company-news/azenta-releases-freezerpro-83-sample-management-update/
Azenta Life Sciences has released FreezerPro version 8.3, enhancing its sample management software to improve sample traceability, inventory control, and workflow efficiency for laboratories. The platform centralizes the tracking of samples, storage, and associated data, supporting regulatory compliance and quick access to critical materials. This update is designed for various laboratory settings to strengthen data visibility and reduce manual errors across research operations.

Azenta management's conference chat will be webcast Nov. 30 at 2:10 p.m. ET.

https://www.stocktitan.net/news/AZTA/azenta-to-participate-in-the-9th-annual-evercore-healthcare-vrvop27ijhzq.html
Azenta Inc. management will participate in the 9th Annual Evercore Healthcare Conference on November 30, 2026, which includes a fireside chat at 2:10 pm ET. A live webcast of the event will be available on Azenta’s investor relations website, with a replay accessible afterward. This conference participation highlights Azenta's engagement with the financial community and its commitment to transparency regarding company activities.

Azenta to Participate in the 9th Annual Evercore Healthcare Conference

https://www.prnewswire.com/news-releases/azenta-to-participate-in-the-9th-annual-evercore-healthcare-conference-302942630.html
Azenta, Inc. (Nasdaq: AZTA) announced its management will participate in the 9th Annual Evercore Healthcare Conference on Monday, November 30, 2026, including a fireside chat at 2:10 pm ET. A live webcast and replay of the event will be available on the company's investor relations website. Azenta is a global provider of life sciences solutions, offering cold-chain sample management and multiomics services to accelerate breakthroughs in drug development and cell therapies.

Azenta to Participate in the 9th Annual Evercore Healthcare Conference

https://www.streetinsider.com/PRNewswire/Azenta+to+Participate+in+the+9th+Annual+Evercore+Healthcare+Conference/27363724.html
Azenta, Inc. (Nasdaq: AZTA) announced its management will participate in the 9th Annual Evercore Healthcare Conference on Monday, November 30, 2026. The company will host a fireside chat at 2:10 pm ET, with a live webcast accessible via its investor relations website and a replay available afterward. Azenta is a leading provider of life sciences solutions, offering cold-chain sample management and multiomics services globally.

Form 4 Azenta Inc: Erik J. Bello (VP Chief Accounting Officer) For: 12 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-azenta-inc-erik-j-bello-vp-chief-accounting-officer-for-12-november-93CH-5708775
This article reports on a Form 4 filing for Azenta Inc, detailing an insider transaction by Erik J. Bello, the VP Chief Accounting Officer, on November 12. The brief announcement confirms the filing's existence and indicates the involvement of a key executive at Azenta Inc (AZTA).
Advertisement

Azenta (AZTA) withholds 4,413 shares for CFO's taxes; transaction was not a market sale.

https://www.stocktitan.net/sec-filings/AZTA/form-4-azenta-inc-insider-trading-activity-d120c615cde9.html
Azenta, Inc. reported that its EVP, CFO, and Treasurer, Lawrence Y. Lin, was granted 23,262 restricted stock units on November 12, 2026. On November 16, 2026, the company withheld 4,413 shares to cover tax obligations arising from the vesting of 10,566 restricted stock units, clarifying that this was not a market sale. The granted units will vest 33-1/3% per year starting November 15, 2027.

Azenta, Inc. Investor News: If You Have Suffered Losses in Azenta, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

https://www.globenewswire.com/news-release/2026/11/15/3403104/673/en/azenta-inc-investor-news-if-you-have-suffered-losses-in-azenta-inc-you-are-encouraged-to-contact-the-rosen-law-firm-about-your-rights.html
The Rosen Law Firm is investigating potential securities claims against Azenta, Inc. (NASDAQ: AZTA) on behalf of investors who may have suffered losses. This investigation follows the resignation of Azenta's President and CEO, John P. Marotta, which led to a 12% drop in the company's stock on August 24, 2026. The firm is preparing a class action lawsuit to recover investor losses and encourages affected shareholders to contact them for more information.

Azenta Q4 2026 EPS Tops Expectations, Revenue Up 5%

https://news.alphastreet.com/azenta-q4-2026-eps-tops-expectations-revenue-up-5/
Azenta, Inc. (AZTA) reported strong Q4 2026 results, with adjusted EPS of $0.28 significantly exceeding Wall Street estimates and revenue growing 5% year-over-year to $167.1M. Despite the impressive beat, the stock traded down slightly, possibly due to investor focus on forward guidance. The company's Sample Management Solutions segment showed robust growth, while multi-omics declined, highlighting areas for future focus.

Azenta dips 7% as investors book profits after earnings surge (AZTA:NASDAQ)

https://seekingalpha.com/news/4671536-azenta-dips-7-as-investors-book-profits-after-earnings-surge
Life sciences company Azenta (AZTA) saw its stock dip over 7% on Thursday, trading at $45.25, as investors booked profits. This retreat followed a significant 21% surge the previous day after the company released its quarterly report, marking its fifth gain in seven sessions.

Azenta guides to $648 million to $660 million in fiscal 2027 revenue and up to 250 basis points of margin expansion

https://mlq.ai/news/azenta-guides-to-648-million-to-660-million-in-fiscal-2027-revenue-and-up-to-250-basis-points-of-margin-expansion/
Azenta, a company specializing in biological sample storage and gene synthesis services, has provided fiscal 2027 guidance expecting revenue between $648 million and $660 million, with organic growth of 3% to 5% and an adjusted EBITDA margin expansion of 200 to 250 basis points. The company also reported a 5% increase in fourth-quarter revenue to $167 million and detailed its recent investments in gene synthesis technology, anticipating these deals to contribute to future growth. Despite a GAAP loss in fiscal 2026 due to a goodwill impairment, Azenta projects improved free cash flow and continued organic growth in the upcoming quarter.
Advertisement

What Azenta (AZTA) Said on Its Q4 Earnings Call

https://www.tradingview.com/news/marketbeat:64fec813b094b:0-what-azenta-azta-said-on-its-q4-earnings-call/
Azenta (AZTA) reported stronger-than-expected Q4 sales and provided an optimistic fiscal 2027 outlook, forecasting faster organic revenue growth and higher profitability. The company is focusing on improving its automated storage business and expanding gene synthesis capabilities through recent acquisitions and licensing agreements. Azenta also detailed financial performance, including adjusted EBITDA and free cash flow projections, alongside insights into its Sample Management Solutions and Multiomics segments.

Azenta, Inc. Stock 12‑Month Price Target Raised to $40.2, Implies 1% Downside

https://www.tradingview.com/news/tradingview:c8edbf9866732:0-azenta-inc-stock-12-month-price-target-raised-to-40-2-implies-1-downside/
Azenta, Inc. (AZTA) has seen its average 12-month price target raised from $37.8 to $40.2 by five analysts, with forecasts ranging from $33 to $54 per share. This new target implies a 1% potential downside based on the Nov. 10 closing price. The consensus rating among six analysts remains a "Buy," with three "Buys" and three "Holds."

Azenta stock hits 52-week high at $47.26 By Investing.com

https://ca.investing.com/news/stock-market-news/azenta-stock-hits-52week-high-at-4726-93CH-4950415
Azenta Inc. (AZTA) stock has reached a new 52-week high of $47.26, reflecting a significant 126% surge in the past six months and a 22% gain year-to-date. Despite concerns of being slightly overvalued, the company recently reported strong fiscal fourth-quarter results, beating Wall Street expectations with non-GAAP earnings of $0.28 per share and revenue of $167 million, driven by improved momentum and new investments in its multiomics business.

Form 8K Azenta Inc For: 10 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-azenta-inc-for-10-november-93CH-4948060
Azenta Inc. (AZTA) filed a Form 8K for November 10, 2026. The article from Investing.com provides this brief notification and includes a Reuters image, noting a slight decrease in AZTA's stock by 1.15%.

AZTA: Azenta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

https://www.quantisnow.com/insight/azenta-inc-filed-sec-form-8-k-results-of-operations-and-6784510
Azenta Inc. (AZTA) filed an SEC Form 8-K, reporting fiscal 2026 revenue of $622 million, up 5% year-over-year, with 2% organic growth, and guided fiscal 2027 revenue to $648-$660 million, expecting 3-5% organic growth. Despite revenue growth and an anticipated EBITDA margin expansion, the company reported a GAAP loss of ($3.50) diluted EPS from continuing operations for FY26 and repurchased $118.2 million in stock.
Advertisement

Azenta, Inc. (AZTA) Tops Q4 EPS by 16c; Offers Guidance

https://www.streetinsider.com/Earnings/Azenta%2C+Inc.+%28AZTA%29+Tops+Q4+EPS+by+16c%3B+Offers+Guidance/27324229.html
Azenta, Inc. (AZTA) reported Q4 EPS of $0.28, significantly surpassing analyst estimates of $0.12 by $0.16. The company also exceeded revenue expectations, bringing in $167 million against a consensus of $160.32 million. Furthermore, Azenta provided optimistic FY2027 revenue guidance of $648-660 million, above the consensus of $639.3 million.

Azenta stock soars over 8% after topping Q4 estimates, guiding above consensus

https://www.investing.com/news/earnings/azenta-stock-soars-over-8-after-topping-q4-estimates-guiding-above-consensus-93CH-5017034
Azenta, Inc. reported strong fourth-quarter results, surpassing analyst expectations with adjusted EPS of $0.28 and revenue of $167 million, driving its stock up over 8% in after-hours trading. The company also issued optimistic fiscal 2027 guidance, projecting revenue between $648 million and $660 million, exceeding the consensus estimate. This performance was attributed to solid growth in Sample Management Solutions and strategic investments, including a $15 million acquisition and share repurchases.

Rosen Law Firm Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

https://www.prnewswire.com/news-releases/rosen-law-firm-encourages-azenta-inc-investors-to-inquire-about-securities-class-action-investigation---azta-302932546.html
The Rosen Law Firm is investigating potential securities claims against Azenta, Inc. (NASDAQ: AZTA) following allegations that the company issued materially misleading business information to investors. This investigation comes after Azenta's CEO resigned, leading to a 12% drop in stock value. Investors who purchased Azenta securities are encouraged to contact the firm to inquire about joining a prospective class action lawsuit.

Azenta investors may claim losses after CEO resignation triggered 12% stock drop

https://pluang.com/en/news-feed/kerugian-investor-azenta-inc-gugatan-kelas-firma-hukum-rosen
The Rosen Law Firm is encouraging Azenta, Inc. investors to contact them regarding potential securities claims after CEO John P. Marotta's resignation on August 22, 2026, caused the company's stock to drop by 12%. The firm is preparing a class action lawsuit to recover investor losses, operating on a contingency fee basis. Shareholders who purchased Azenta securities during this period may be eligible for compensation if the company provided misleading business information.

Azenta, Inc. (AZTA) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/AZTA/
This article provides a comprehensive overview of Azenta, Inc. (AZTA) stock, including its current price, historical data, financial performance, and analyst ratings. It details the company's operations in biological and chemical compound sample management for the life sciences industry, highlighting its Sample Management Solutions and Multiomics segments. The report also includes key financial statistics, earnings trends, and performance comparisons against the S&P 500.
Advertisement

Form 8K Azenta Inc For: 30 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-8k-azenta-inc-for-30-october-93CH-2771090
Azenta Inc. has filed a Form 8K for October 30, 2026. The article from Investing.com mentions the filing and includes general market data and news, but does not provide details about the content of the 8K filing itself. It primarily serves as a notice of the filing.

Azenta investors urged to join class action over CEO resignation and stock drop

https://pluang.com/en/news-feed/kerugian-investor-azenta-inc-gugatan-kelas-hukum-rosen
The Rosen Law Firm is investigating potential securities claims against Azenta, Inc. after CEO John P. Marotta's sudden resignation on August 22, 2026, caused a 12% stock price drop. The firm is preparing a class action lawsuit, alleging that Azenta may have provided misleading business information. Shareholders who bought Azenta securities are encouraged to contact the firm for more information regarding potential compensation.

Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities

https://www.moomoo.com/news/post/1003010239/azenta-announces-strategic-investments-to-advance-the-next-generation-of
Azenta, Inc. is making strategic investments to enhance its GENEWIZ gene synthesis capabilities, aiming to expand capacity, improve efficiency, and accelerate product development. These investments include new facilities in the U.S. and Germany, along with advanced automation and proprietary technologies, to meet increasing demand for complex gene constructs and support genomics research.

Azenta, Inc. Investor News: If You Have Suffered Losses in Azenta, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

https://www.globenewswire.com/news-release/2026/10/30/3392660/0/en/azenta-inc-investor-news-if-you-have-suffered-losses-in-azenta-inc-you-are-encouraged-to-contact-the-rosen-law-firm-about-your-rights.html
The Rosen Law Firm is investigating potential securities claims against Azenta, Inc. (NASDAQ: AZTA) on behalf of investors who may have suffered losses due to allegedly misleading business information. This investigation follows the resignation of Azenta's President and CEO, John P. Marotta, which led to a 12% drop in the company's stock. Investors who purchased Azenta securities are encouraged to contact The Rosen Law Firm to explore their rights.

Azenta Secures Exclusive Elegen License and Finalizes SynPlexity Acquisition to Boost DNA Synthesis

https://kalkinemedia.com/us/news/announcements/azenta-secures-exclusive-elegen-license-and-finalizes-synplexity-acquisition-to-boost-dna-synthesis
Azenta, Inc. has announced two strategic moves to enhance its DNA synthesis capabilities: an exclusive, royalty-free license agreement with Elegen Corp. for gene synthesis and cell-free cloning technology, and the acquisition of SynPlexity Inc., a firm specializing in DNA assembly technology. These transactions are expected to involve a capital investment of $32 million to $71 million and are aimed at advancing Azenta's GENEWIZ gene synthesis services and regional manufacturing capacity.
Advertisement

Azenta Acquires SynPlexity, Signs Exclusive Elegen Licensing Deal to Expand GENEWIZ Capabilities

https://www.citybiz.co/article/927043/azenta-acquires-synplexity-signs-exclusive-elegen-licensing-deal-to-expand-genewiz-capabilities/
Azenta, Inc. (Nasdaq: AZTA) has acquired SynPlexity Inc. and entered into an exclusive licensing agreement with Elegen Corp. to bolster its GENEWIZ gene synthesis business. These strategic moves aim to enhance GENEWIZ’s capabilities in DNA synthesis, high-throughput gene assembly, and synthetic biology, positioning it to meet increasing demand from pharmaceutical, biotechnology, and research organizations. The financial terms of these transactions were not disclosed.

Azenta licenses Elegen tech, acquires SynPlexity for GENEWIZ unit

https://www.investing.com/news/company-news/azenta-licenses-elegen-tech-acquires-synplexity-for-genewiz-unit-93CH-4987392
Azenta Inc. (NASDAQ:AZTA) has announced an exclusive licensing agreement with Elegen Corp. and the acquisition of SynPlexity Inc. to enhance the capabilities of its GENEWIZ business unit. These strategic moves aim to expand GENEWIZ's offerings in synthetic biology, protein engineering, and AI-enabled drug discovery applications, leveraging Elegen's cell-free DNA synthesis platform and SynPlexity's pooled gene assembly technology. Financial terms of the transactions were not disclosed but are expected to be discussed during Azenta's fourth-quarter fiscal 2026 earnings call.

Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities

https://www.prnewswire.com/news-releases/azenta-announces-strategic-investments-to-advance-the-next-generation-of-genewiz-gene-synthesis-capabilities-302924585.html
Azenta, Inc. announced strategic investments to enhance its GENEWIZ gene synthesis capabilities through an exclusive licensing agreement with Elegen Corp. and the acquisition of SynPlexity Inc. These moves are aimed at strengthening GENEWIZ's competitive position by expanding product offerings, improving DNA quality and delivery speed, and facilitating high-throughput discovery workflows for biologics development. The investments are expected to accelerate growth in synthetic biology, protein engineering, and AI-enabled drug discovery applications.

Azenta Announces Fiscal 2026 Fourth Quarter and Full Year Conference Call and Webcast

https://www.streetinsider.com/PRNewswire/Azenta+Announces+Fiscal+2026+Fourth+Quarter+and+Full+Year+Conference+Call+and+Webcast/27249080.html
Azenta, Inc. (Nasdaq: AZTA) announced its fiscal fourth quarter and full year 2026 earnings for the period ending September 30, 2026, will be released on Tuesday, November 10, 2026, after market close. The company will host a conference call and live webcast to discuss these financial results the following day, Wednesday, November 11, 2026, at 8:30 a.m. Eastern Time. Analysts, investors, and media can access the webcast via the Azenta website.

Azenta Announces Fiscal 2026 Fourth Quarter and Full Year Conference Call and Webcast

https://www.tradingview.com/news/prnewswire:2378bde026acb:0-azenta-announces-fiscal-2026-fourth-quarter-and-full-year-conference-call-and-webcast/
Azenta, Inc. (Nasdaq: AZTA) will release its fiscal fourth quarter and full year 2026 earnings on Tuesday, November 10, 2026, after market close. The company will host a conference call and live webcast to discuss these financial results on Wednesday, November 11, 2026, at 8:30 a.m. Eastern Time. Investors and media can access the webcast via the Azenta website.
Advertisement

Azenta, Inc. Investor News: If You Have Suffered Losses in Azenta, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

https://www.globenewswire.com/news-release/2026/10/25/3387741/673/en/azenta-inc-investor-news-if-you-have-suffered-losses-in-azenta-inc-you-are-encouraged-to-contact-the-rosen-law-firm-about-your-rights.html
The Rosen Law Firm is investigating potential securities claims against Azenta, Inc. (NASDAQ: AZTA) on behalf of shareholders who suffered losses. This investigation follows the resignation of Azenta's President and CEO, John P. Marotta, which led to a 12% drop in the company's stock on August 24, 2026. Shareholders are encouraged to contact the firm for information on joining a prospective class action lawsuit.

Form 4 Azenta Inc: Martin D. Madaus (Interim CEO) For: 22 October

https://ng.investing.com/news/stock-market-news/form-4-azenta-inc-martin-d-madaus-interim-ceo-for-22-october-93CH-2754376
This article reports on a Form 4 filing for Azenta Inc. It indicates that Martin D. Madaus, the Interim CEO, was involved in a transaction on October 22. The filing is an official SEC document detailing changes in ownership of company stock by an insider.

Not a market sale: Azenta (AZTA) interim CEO had 1,294 shares withheld for taxes.

https://www.stocktitan.net/sec-filings/AZTA/form-4-azenta-inc-insider-trading-activity-7f8510591585.html
Azenta, Inc.'s Interim CEO, Martin D. Madaus, had 1,294 common shares withheld to cover tax obligations related to the vesting of 3,055 restricted stock units on October 22, 2026. This transaction was not a market sale and occurred at a price of $36.01 per share, leaving him with 41,308 directly held common shares.

Form 4 Azenta Inc: Martin D. Madaus (Interim CEO) For: 22 October

https://uk.investing.com/news/stock-market-news/form-4-azenta-inc-martin-d-madaus-interim-ceo-for-22-october-93CH-4928500
This article reports on a Form 4 filing for Azenta Inc., specifically detailing activity by Interim CEO Martin D. Madaus for October 22. Form 4s disclose changes in beneficial ownership of securities by a company's officers, directors, and principal stockholders. The article is a brief notification of this financial filing.

Azenta, Inc. Investor News: If You Have Suffered Losses in

https://www.globenewswire.com/news-release/2026/10/17/3382849/673/en/azenta-inc-investor-news-if-you-have-suffered-losses-in-azenta-inc-you-are-encouraged-to-contact-the-rosen-law-firm-about-your-rights.html
The Rosen Law Firm is investigating potential securities claims on behalf of Azenta, Inc. (NASDAQ: AZTA) shareholders due to allegations that the company may have issued misleading business information. This follows the resignation of Azenta's President and CEO, John P. Marotta, on August 22, 2026, which caused the stock to fall 12%. Investors who purchased Azenta securities are encouraged to contact the firm for information on joining a prospective class action.
Advertisement

Azenta, Inc. (AZTA) Investigation: Bronstein, Gewirtz & Grossman

https://natlawreview.com/press-releases/azenta-inc-azta-investigation-bronstein-gewirtz-grossman-llc-encourages-0
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential claims against Azenta, Inc. (NASDAQ: AZTA) following a 12% stock price drop on August 24, 2026. This decline occurred after the company announced the resignation of its President and CEO, John P. Marotta, on August 22, 2026. The firm is encouraging investors who purchased Azenta securities to contact them to learn more about the investigation.

Azenta, Inc. (AZTA) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_3917_QuantitativeReport_1790726400000
This article provides an Argus research report summary for Azenta Inc. (AZTA), a life sciences solutions provider. The report, dated September 30, 2026, includes a current price of $34.09 and offers insights into the company's performance and future outlook. Users can upgrade to access the full premium research report and related content.

Azenta, Inc. (AZTA) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_3917_QuantitativeReport_1790726400000
This article provides a brief summary of Azenta Inc. (AZTA), a life sciences solutions provider. Argus issued a report on AZTA on September 30, 2026, and the current price is $34.09. The report suggests an upgrade to access premium tools and detailed insights for this company.

Azenta, Inc. Investor News: If You Have Suffered Losses in

https://www.globenewswire.com/de/news-release/2026/10/12/3379144/0/en/azenta-inc-investor-news-if-you-have-suffered-losses-in-azenta-inc-you-are-encouraged-to-contact-the-rosen-law-firm-about-your-rights.html
The Rosen Law Firm is investigating potential securities claims on behalf of Azenta, Inc. (NASDAQ: AZTA) shareholders who may have suffered losses due to allegedly misleading business information. The investigation follows a 12% drop in Azenta's stock on August 24, 2026, after the resignation of its President and CEO. Shareholders are encouraged to contact the firm to learn about joining a prospective class action to recover investor losses.

Azenta, Inc. Investor News: If You Have Suffered Losses in

https://www.globenewswire.com/news-release/2026/10/12/3379144/673/en/azenta-inc-investor-news-if-you-have-suffered-losses-in-azenta-inc-you-are-encouraged-to-contact-the-rosen-law-firm-about-your-rights.html
The Rosen Law Firm is investigating potential securities claims against Azenta, Inc. (NASDAQ: AZTA) following allegations of misleading business information. This investigation comes after Azenta's stock fell 12% on August 24, 2026, subsequent to the resignation of its President and CEO. Investors who purchased Azenta securities are encouraged to contact the firm regarding a potential class action to recover losses.
Advertisement

Azenta, Inc. Investor News: If You Have Suffered Losses in

https://www.globenewswire.com/news-release/2026/10/09/3378401/0/en/azenta-inc-investor-news-if-you-have-suffered-losses-in-azenta-inc-you-are-encouraged-to-contact-the-rosen-law-firm-about-your-rights.html
The Rosen Law Firm is investigating potential securities claims against Azenta, Inc. (NASDAQ: AZTA) on behalf of investors who suffered losses. This investigation follows the resignation of Azenta's President and CEO, John P. Marotta, on August 22, 2026, which led to a 12% stock drop. The firm encourages affected shareholders to join a prospective class action to seek compensation.

Azenta, Inc. Investor News: If You Have Suffered Losses in

https://www.globenewswire.com/news-release/2026/10/12/3379144/0/en/azenta-inc-investor-news-if-you-have-suffered-losses-in-azenta-inc-you-are-encouraged-to-contact-the-rosen-law-firm-about-your-rights.html
The Rosen Law Firm is investigating potential securities claims against Azenta, Inc. (NASDAQ: AZTA) on behalf of investors who may have suffered losses due to allegedly misleading business information. This investigation follows the resignation of Azenta's President and CEO on August 22, 2026, which led to a 12% drop in the company's stock. The firm is preparing a class action lawsuit to recover investor losses.

Azenta, Inc. (AZTA) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_3917_QuantitativeReport_1791331200000/
Argus has raised its target price for Azenta Inc. (AZTA) to $41.00. Azenta Inc. is described as a provider of life sciences solutions that facilitates faster breakthroughs and therapies. The report also mentions the current stock price of $37.72.

Azenta, Inc. Investor News: If You Have Suffered Losses in

https://www.globenewswire.com/news-release/2026/10/09/3378401/673/en/azenta-inc-investor-news-if-you-have-suffered-losses-in-azenta-inc-you-are-encouraged-to-contact-the-rosen-law-firm-about-your-rights.html
The Rosen Law Firm is investigating potential securities claims on behalf of Azenta, Inc. (NASDAQ: AZTA) shareholders who suffered losses. This investigation follows the resignation of Azenta's President and CEO, John P. Marotta, which led to a 12% drop in the company's stock. Investors are encouraged to contact the firm to join a prospective class action to recover losses without upfront fees.

Azenta Inc (BA3.MU) Analyst insights, Price targets and Recommendations

https://uk.finance.yahoo.com/quote/BA3.MU/analyst-insights/
This article provides analyst insights, price targets, and recommendations for Azenta Inc (BA3.MU). It lists several reiterations of "Buy" and "Outperform" ratings from Needham and Evercore ISI Group between September 2026 and March 2026. The stock is currently trading at 32.40 EUR, down 10.50%.
Advertisement

Azenta to Close Three Labs, Cut Jobs in $11M-$13M Restructuring

https://www.minichart.com.sg/2026/10/07/azenta-to-close-three-labs-cut-jobs-in-11m-13m-restructuring/
Azenta, Inc. (Nasdaq: AZTA) has approved a restructuring plan within its Multiomics segment, involving job cuts and the closure of three North American laboratory sites. This move is expected to generate approximately $11 million in annualized cost savings but will incur $11 million to $13 million in pre-tax charges, primarily for asset impairment and employee severance. The company aims to complete most actions by March 31, 2027, with the goal of improving operating efficiency and consolidating its North American laboratory network.

Azenta Inc (AZTA) Shares Fall 7.9% -- What GF Score of 83 Tells Investors

https://www.gurufocus.com/news/9112406/azenta-inc-azta-shares-fall-79-what-gf-score-of-83-tells-investors
Azenta Inc (AZTA) shares fell 7.9% to $39.35, yet its GF Score of 83/100 indicates strong overall fundamentals. The stock is considered "modestly undervalued" by GF Value, suggesting a potential upside, despite the company currently being unprofitable. Both gurus and insiders have been increasing their stakes, signaling confidence in its future performance.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA

https://www.financialcontent.com/article/gnwcq-2026-10-6-investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-azenta-inc-azta
Pomerantz LLP is investigating potential securities fraud and unlawful business practices by Azenta, Inc. (AZTA) and its officers/directors. This investigation follows the resignation of CEO John Marotta on August 24, 2026, which led to a 12.09% drop in Azenta's stock price. Investors affected by the stock drop are encouraged to contact Pomerantz LLP.

Rosen Law Firm Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

https://www.prnewswire.com/news-releases/rosen-law-firm-encourages-azenta-inc-investors-to-inquire-about-securities-class-action-investigation---azta-302899023.html
The Rosen Law Firm is investigating potential securities claims against Azenta, Inc. (NASDAQ: AZTA) on behalf of investors. This follows allegations that Azenta may have issued materially misleading business information, which led to a 12% stock drop after its CEO and President resigned in August 2026. The firm is preparing a class action lawsuit to recover investor losses.

Azenta stock hits 52-week high at 41.84 USD By Investing.com

https://ng.investing.com/news/stock-market-news/azenta-stock-hits-52week-high-at-4184-usd-93CH-2720261
Azenta Inc. (AZTA) stock reached a new 52-week high of $41.84, reflecting a significant 21.66% increase over the past year and a 52% return in the last six months. This milestone is supported by management's aggressive share buybacks and the company's strong cash position relative to debt. Despite trading slightly above its Fair Value according to InvestingPro, Azenta recently surpassed Q3 2026 earnings and revenue expectations, driven by demand in sample management and multiomics.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement